Fig. 4: The pooled proportion of neutralizing antibody development following primary SARS-CoV-2 vaccination in patients with hematologic malignancies. | Blood Cancer Journal

Fig. 4: The pooled proportion of neutralizing antibody development following primary SARS-CoV-2 vaccination in patients with hematologic malignancies.

From: Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis

Fig. 4

The pooled analysis of 21 studies containing 2011 patients with hematologic malignancies showed that the pooled proportion of neutralizing antibody development was 52.8% (95% confident interval [CI], 45.8–59.7%).

Back to article page